公开(公告)号：WO2013106269A3

公开(公告)日：2014-09-04

申请号：PCT/US2013020483

申请日：2013-01-07

Applicant: IDEXX LAB INC

Inventor： CHAN EUGENE ,  NASSIF KEITH

IPC: G01N33/24

CPC classification number: G01N33/573 ,  G01N33/54366 ,  G01N35/00029 ,  G01N2035/00138 ,  G01N2333/918

Abstract: An immunoassay test slide for use in a dry chemistry analytical instrument includes a slide housing or case formed from two matable sections - a slide cover piece and a slide bottom piece. The slide housing defines an interior cavity in which is situated a sheet-like porous carrier matrix. The slide cover piece has an opening formed through the thickness thereof to expose a central portion of the fluid flow matrix so that a precise volume of fluid sample of blood, serum or the like, preferably pre-mixed with a conjugate reagent, and precise volumes of a wash reagent and a substrate (detector reagent), may be deposited on the matrix through the cover opening by a metering device of the analytical instrument.

Abstract translation: 用于干化学分析仪器的免疫测定试验载玻片包括由两个可配置部分形成的滑动壳体或壳体 - 滑动盖片和滑动底部片。 滑动壳体限定内部空腔，其中位于片状多孔载体矩阵中。 滑动盖件具有通过其厚度形成的开口，以暴露流体流动基体的中心部分，使得精确体积的血液，血清等的液体样品优选与共轭试剂预混合，并且精确体积 洗涤剂和底物（检测剂试剂）可以通过分析仪器的计量装置通过盖开口沉积在基质上。

公开(公告)号：WO2009002922A3

公开(公告)日：2009-12-30

申请号：PCT/US2008067882

申请日：2008-06-23

Applicant: IDEXX LAB INC ,  MURTHY YERRAMILLI V S N ,  OBARE EDWARD

Inventor： MURTHY YERRAMILLI V S N ,  OBARE EDWARD

IPC: A01N43/04 ,  A61K31/20

CPC classification number: A61K31/7048

Abstract: The invention relates to a method of treating a bacterial infection In an animal by administering a single dose of roxithromycin The roxithromycin is formulated in a solution comprising propylene glycol in glycerol Animals which may treated include, cats, dogs and cattle, and the formulation may be administered orally or by subcutaneous injection, and the formulation is effective against a wide variety of gram positive and gram negative bacterial species.

Abstract translation: 本发明涉及一种治疗细菌感染的方法在动物中通过施用单剂量的罗红霉素将罗红霉素配制在甘油中的丙二醇溶液中，可以处理的动物包括猫，狗和牛，制剂可以是 口服或通过皮下注射给药，并且该制剂对于各种革兰氏阳性和革兰氏阴性细菌物种是有效的。

公开(公告)号：WO2009143081A2

公开(公告)日：2009-11-26

申请号：PCT/US2009044401

申请日：2009-05-18

Applicant: IDEXX LAB INC ,  DIVERGENCE INC ,  ELSEMORE DAVID ALLEN ,  FLYNN LAURIE A ,  CRAWFORD MICHAEL

Inventor： ELSEMORE DAVID ALLEN ,  FLYNN LAURIE A ,  CRAWFORD MICHAEL

IPC: C12Q1/70 ,  C07K14/435 ,  C07K16/18 ,  G01N33/569

CPC classification number: C07K16/18 ,  C07K14/43536 ,  G01N33/5308

Abstract: Methods, devices, kits and compositions for detecting the presence or absence of roundworm in a fecal sample are disclosed herein. The methods, devices, kits and compositions of the present invention may be used to confirm the presence or absence of roundworm in a fecal sample from a mammal that may also be infected with one or more of hookworm, whipworm, and heartworm. Confirmation of the presence or absence of roundworm in the mammal may be made, for example, for the purpose of selecting an optimal course of treating the mammal and/or for the purpose of determining whether the mammal has been rid of the infection after treatment has been initiated.

Abstract translation: 本文公开了用于检测粪便样品中蛔虫存在或不存在的方法，装置，试剂盒和组合物。 本发明的方法，装置，试剂盒和组合物可以用于确认来自哺乳动物的粪便样品中是否存在蛔虫，所述蛔虫样品也可能被钩虫，鞭虫和心丝虫中的一种或多种感染。 可以确认哺乳动物中蛔虫的存在或不存在，例如，为了选择治疗哺乳动物和/或为了确定哺乳动物是否已经在治疗后已经除去感染的目的的最佳方法 已经启动

公开(公告)号：WO2007097888A3

公开(公告)日：2008-02-28

申请号：PCT/US2007002693

申请日：2007-02-01

Applicant: IDEXX LAB INC ,  MURTHY YERRAMILLI V S N

Inventor： MURTHY YERRAMILLI V S N

IPC: A61K31/47 ,  A61K31/4709

CPC classification number: A61K31/722 ,  A61K9/0095 ,  A61K9/10 ,  A61K31/47 ,  A61K47/12 ,  A61K47/40 ,  A61K2300/00

Abstract: The invention relates to pharmaceutical compositions that are a solution of a salt formed between a fluoroquinolone and a carboxylic acid, a cyclodextrin, and a pharmaceutically acceptable organic solvent and to methods of treating a condition in an animal by administering to an animal in need thereof the pharmaceutical composition of the invention.

Abstract translation: 本发明涉及药物组合物，其是在氟喹诺酮和羧酸，环糊精和药学上可接受的有机溶剂之间形成的盐的溶液，并且涉及通过给予需要其的动物治疗动物中的病症的方法 本发明的药物组合物。

公开(公告)号：WO2006058161A3

公开(公告)日：2007-11-22

申请号：PCT/US2005042614

申请日：2005-11-23

Applicant: IDEXX LAB INC ,  MISENER GARLAND CHRISTIAN ,  HARJU PHILIP N ,  KOSTURA DANIEL J SR

Inventor： MISENER GARLAND CHRISTIAN ,  HARJU PHILIP N ,  KOSTURA DANIEL J SR

IPC: G01N21/47

CPC classification number: G01N21/474 ,  G01N21/8483 ,  G01N2021/4759

Abstract: A light source for a reflectometer which is used in a chemical analyzer includes a plurality of light emitting devices. Some of the light emitting devices emit light of different wavelengths. The light emitting devices are arcuately arranged about a circle having a predetermined radius. Adjacent light emitting devices are spaced from each other a predetermined distance. The light emitting devices are positioned to direct light emitted therefrom to an illumination plane. At least two, but preferably three or four, of the light emitting devices emit light of substantially the same wavelength and are illuminated simultaneously to provide a volume of substantially homogenous irradiance at the illumination plane.

Abstract translation: 用于化学分析仪的反射计的光源包括多个发光装置。 一些发光器件发射不同波长的光。 发光器件围绕具有预定半径的圆弧弧形地布置。 相邻的发光器件彼此隔开预定距离。 发光器件被定位成将从其发射的光引导到照明平面。 至少两个，但优选三个或四个发光器件发射基本上相同波长的光并且被同时照射，以在照明平面处提供基本均匀的辐照度的体积。

公开(公告)号：WO2006107924B1

公开(公告)日：2007-06-07

申请号：PCT/US2006012432

申请日：2006-04-04

Applicant: IDEXX LAB INC ,  KRAH EUGENE REGIS III ,  BEALL MELISSA

Inventor： KRAH EUGENE REGIS III ,  BEALL MELISSA

IPC: C07K14/29 ,  A61K39/02 ,  G01N33/569

CPC classification number: A61K39/0233 ,  A61K2039/55505 ,  A61K2039/55566 ,  A61K2039/55594 ,  C07K14/29 ,  G01N33/56911 ,  G01N2333/29 ,  G01N2469/20 ,  A61K2300/00

Abstract: Ehrlichia

Abstract translation: 埃立克体

公开(公告)号：WO2006050002A3

公开(公告)日：2006-12-21

申请号：PCT/US2005038664

申请日：2005-10-27

Applicant: IDEXX LAB INC ,  MURTHY YERRAMILLI V S N

Inventor： MURTHY YERRAMILLI V S N

IPC: A61K9/14 ,  A61F2/00 ,  A61K9/20 ,  A61K9/22 ,  A61K9/48 ,  C07B55/00 ,  C07C51/487 ,  C07D233/64

CPC classification number: A61K31/198 ,  A61K31/7056 ,  A61K31/7076 ,  A61K2300/00

Abstract: The invention relates to pharmaceutical compositions that provide sustained­release of a pharmaceutically active compound and to methods of treating or preventing a condition in an animal by administering the pharmaceutical compositions to the animal by injection. When the pharmaceutical compositions are administered to an animal by injection, they form a drug depot that releases the pharmaceutically active compound over time. The pharmaceutical compositions can also be administered orally.

Abstract translation: 本发明涉及提供药物活性化合物的持续释放的药物组合物，以及通过将药物组合物通过注射给予动物来治疗或预防动物中的病症的方法。 当药物组合物通过注射施用于动物时，它们形成长效释放药物活性化合物的长效制剂。 药物组合物也可以口服给药。

公开(公告)号：WO2006022882A3

公开(公告)日：2006-10-26

申请号：PCT/US2005012645

申请日：2005-04-15

Applicant: IDEXX LAB INC ,  BEALL MELISSA ,  HUTH STACEY PAZAR ,  KRAH EUGENE REGIS

Inventor： BEALL MELISSA ,  HUTH STACEY PAZAR ,  KRAH EUGENE REGIS

IPC: C12N9/20 ,  C07H21/04 ,  C07K16/40 ,  C12N1/18 ,  C12N9/32 ,  C12N15/55 ,  C12Q1/68 ,  G01N33/573 ,  G01N33/577

CPC classification number: G01N33/573 ,  C07K16/40 ,  C12N9/20 ,  G01N2333/918

Abstract: Isolated nucleic acid molecules having a nucleotide sequence encoding canine pancreatic lipase polypeptides, allelic variants and fragments thereof. Vectors and host cells containing the polynucleotide sequences and methods for expressing the polypeptides. Monoclonal antibodies that specifically binds to the canine pancreatic lipase polypeptides. Cell lines secreting the monoclonal antibodies. Methods for determining the presence or amount of canine pancreatic lipase in a biological sample. The methods include using the monoclonal antibodies to specifically bind to canine pancreatic lipase polypeptides. The method includes using standards of recombinant canine pancreatic lipase. Devices and kits for performing methods for detecting canine pancreatic lipase in biological samples.

Abstract translation: 具有编码犬胰脂肪酶多肽的核苷酸序列的分离的核酸分子，等位变体及其片段。 含有多核苷酸序列的载体和宿主细胞和用于表达多肽的方法。 特异性结合犬胰脂肪酶多肽的单克隆抗体。 分泌单克隆抗体的细胞系。 确定生物样品中犬胰脂肪酶的存在或量的方法。 所述方法包括使用单克隆抗体特异性结合犬胰脂肪酶多肽。 该方法包括使用重组犬胰脂肪酶标准品。 用于检测生物样品中犬胰脂肪酶的方法的装置和试剂盒。

公开(公告)号：WO2004091541A3

公开(公告)日：2004-12-16

申请号：PCT/US2004012030

申请日：2004-04-15

Applicant: IDEXX LAB INC ,  MURTHY YERRAMILLI V S N ,  SUVA ROBERT H

Inventor： MURTHY YERRAMILLI V S N ,  SUVA ROBERT H

IPC: A61K20060101 ,  A61K9/00 ,  A61K31/65 ,  A61K47/10 ,  A61K47/12 ,  A61K47/14 ,  A61K47/20 ,  A61K47/22 ,  A61K47/26

CPC classification number: A61K31/65 ,  A61K9/0019 ,  A61K9/0024 ,  A61K47/10 ,  A61K47/12 ,  A61K47/14 ,  A61K47/20 ,  A61K47/22 ,  A61K47/26

Abstract: The present invention provides compositions and methods for extending the release times and lowering the toxicity of pharmacologically active compounds. The compounds comprise a salt of the pharmacologically active compound with a lipophilic counterion and a pharmaceutically acceptable water soluble solvent combined together to form an injectable composition. The lipophilic counterion may be a saturated or unsaturated C8-C22 fatty acid, and preferably may be a saturated or unsaturated C10-C18 fatty acid. The compounds precipitate in aqueous environments. When injected into a mammal, at least a portion of the composition precipitates and releases the active compound over time. Thus, the composition forms a slowly releasing drug depot of the active compound in the mammal. Therefore, the present invention enables one to provide a controlled dose administration of the active compound for a period of up to 15 days or even longer. Many compounds can be administered according to the present invention including, but not limited to, tilmicosin, oxytetracycline, metoprolol, fluoxetine, roxithromycin, and turbinafine.

Abstract translation: 本发明提供用于延长释放时间并降低药理活性化合物的毒性的组合物和方法。 化合物包含药理活性化合物的盐与亲脂性抗衡离子和药学上可接受的水溶性溶剂组合在一起形成可注射组合物。 亲油抗衡离子可以是饱和或不饱和的C 8 -C 22脂肪酸，优选可以是饱和或不饱和的C 10 -C 18脂肪酸。 化合物在水性环境中沉淀。 当注射到哺乳动物中时，组合物的至少一部分随时间沉淀并释放活性化合物。 因此，组合物在哺乳动物中形成缓慢释放活性化合物的药物贮库。 因此，本发明使得能够提供活性化合物的受控剂量给药长达15天甚至更长时间。 根据本发明可以施用许多化合物，包括但不限于替米考星，土霉素，美托洛尔，氟西汀，罗红霉素和头孢噻吩。

公开(公告)号：WO03034988A2

公开(公告)日：2003-05-01

申请号：PCT/US0233300

申请日：2002-10-18

Applicant: IDEXX LAB INC ,  MURTHY YERRAMILLI V S N ,  SUVA ROBERT

Inventor： MURTHY YERRAMILLI V S N ,  SUVA ROBERT

IPC: A61K9/00 ,  A61K9/10 ,  A61K31/137 ,  A61K31/138 ,  A61K31/165 ,  A61K31/18 ,  A61K31/245 ,  A61K31/4704 ,  A61K31/496 ,  A61K31/505 ,  A61K31/65 ,  A61K31/7036 ,  A61K31/7048 ,  A61K47/10 ,  A61K47/12 ,  A61K47/14 ,  A61K47/20 ,  A61K47/22 ,  A61K47/26 ,  A61K47/32 ,  A61K47/34 ,  A61P23/02 ,  A61P31/04 ,  A61K

CPC classification number: A61K31/00 ,  A61K9/0019 ,  A61K9/0024 ,  A61K31/24 ,  A61K31/496 ,  A61K31/65 ,  A61K31/7034 ,  A61K31/7048 ,  A61K47/10 ,  A61K47/12 ,  A61K47/14 ,  A61K47/20 ,  A61K47/22 ,  A61K47/26 ,  A61K2300/00

Abstract: The present invention provides compositions and methods for extending the release times and lowering the toxicity of pharmacologically active compounds. The compounds comprise a salt of the pharmacologically active compound with a lipophilic counterion and a pharmaceutically acceptable water soluble solvent combined together to form an injectable composition. The lipophilic counterion may be a saturated or unsaturated C8-C22 fatty acid, and preferably may be a saturated or unsaturated C10-C18 fatty acid. When injected into a mammal, at least a portion of the composition precipitates and releases the active compound over time. Thus, the composition forms a slowly releasing drug depot of the active compound in the mammal. Therefore, the present invention enables one to provide a controlled dose administration of the active compound for a periods of up to 15 days or even longer. Many compounds can be administered according to the present invention including, but not limited to, tilmicosin, oxytetracycline, metoprolol, fluoxetine, roxithromycin, and turbinafine.

Abstract translation: 本发明提供用于延长释放时间和降低药理活性化合物毒性的组合物和方法。 所述化合物包含药理活性化合物与亲脂性抗衡离子的盐和药学上可接受的水溶性溶剂混合在一起以形成可注射组合物。 亲脂平衡离子可以是饱和或不饱和C 8 -C 22脂肪酸，并且优选可以是饱和或不饱和C 10 -C 18脂肪酸。 当注射到哺乳动物中时，至少一部分组合物随时间沉淀并释放活性化合物。 因此，该组合物在哺乳动物中形成活性化合物的缓释药物贮库。 因此，本发明使得能够提供控制剂量的活性化合物给药达最多15天甚至更长的时间。 根据本发明可以施用许多化合物，包括但不限于替米考星，土霉素，美托洛尔，氟西汀，罗红霉素和透明颤菌素。